Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2025-26/69

August 07, 2025

To, The Manager **BSE Limited** Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Manager **National Stock Exchange of India Limited** Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	**Scrip Symbol – BIOCON**

Subject: Press Release on financial results for the quarter ended June 30, 2025.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled **"Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15% EBITDA at Rs 829 Cr; Up 19%*; PBT (before exceptional item) at Rs 97 Cr, Up 72%* Biosimilars Up 18%, CRDMO Up 11% and Generics Up 6%**" pertaining to the un-audited consolidated financial results of Biocon Limited for the quarter ended June 30, 2025.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

EKTA AGARWAL
Digitally signed by EKTA AGARWAL
Date: 2025.08.07 20:06:19 +05'30'

Ekta Agarwal
Interim Company Secretary and Compliance Officer
Membership No.: FCS 11388

Enclosed: Press Release and Fact Sheet

Press Release

Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15%
EBITDA at Rs 829 Cr; Up 19%*;
PBT (before exceptional item) at Rs 97 Cr, Up 72%*
Biosimilars Up 18%, CRDMO Up 11% and Generics Up 6%

Bengaluru, Karnataka, India: Aug 7, 2025:

Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the fiscal first quarter ended June 30, 2025.

Q1FY26 | Financial Highlights

Rs 4,022 Crore
CONSOLIDATED REVENUE
Up 15%*
(like-for like basis)

Rs 3,942 Crore
OPERATING REVENUE
Up 15%

**(like-for like basis after adjusting for BFI divestment gain in Q1FY25)*

Rs 829 Crore
EBITDA
Up 19%*

21%
EBITDA MARGIN

Rs 97 Crore
PBT
(before exceptional item)
Up 72%*

Rs 1,003 Crore
CORE EBITDA
Up 11%

25%
CORE EBITDA MARGIN

Rs 205 Crore
NET R&D INVESTMENT
7% of Revenue
(ex-Syngene)

Q1FY26 | Business Segments Revenue

Rs 697 Crore, Up 6% YoY
GENERICS: APIs & Generic Formulations

Rs 2,458 Crore, Up 18% YoY
BIOSIMILARS: Biocon Biologics

Rs 875 Crore, Up 11% YoY
CRDMO[&] : Syngene

[&] *Our Research Services Business segment has been renamed as CRDMO, representing Syngene's business*



Note: Revenue contribution as a % of Revenue from Operations

Leadership Comments

BIOCON GROUP

"*Biocon opened FY26 with a strong performance, driven by continued gains in Biosimilars and CRDMO, and a steady showing in Generics. Operating Revenue rose 15% YoY to Rs 3,942 crore, with EBITDA up 19% on a like-for-like basis, demonstrating operating leverage and the robustness of our businesses.*

The recent QIP has strengthened our balance sheet and enables us to increase our ownership in Biocon Biologics by facilitating the exit of structured equity investors, aligning capital structure with long-term strategic priorities.

Key developments this quarter include the launch of Yesafili™ in Canada, our tenth biosimilar globally, and USFDA approval for Insulin Aspart, our second interchangeable biosimilar Insulin, further deepening our presence in the U.S. insulin market.

With execution momentum across all businesses and expanded capacity through acquisitions in the U.S. by Syngene and Biocon Generics, we are well-positioned to drive long-term value creation in FY26 and beyond." **- Kiran Mazumdar-Shaw, Chairperson, Biocon Group.**

BIOCON GENERICS

"The generics business' performance in the first quarter was in line with expectations, delivering a 6% revenue growth over the previous year. Growth in the quarter was primarily driven by revenues from recent drug product launches, including Liraglutide in the E.U., and Dasatinib and Lenalidomide in the U.S., supported by higher volumes in our API business. The sequential financial performance reflects the one-time positive impact of Lenalidomide launch quantities in Q4FY25. The capitalization of new manufacturing facilities in the previous fiscal impacted margins.

We remain focused on launching new products, including the commercialization of Liraglutide across key strategic markets." **- Siddharth Mittal, CEO & Managing Director, Biocon Limited.**

BIOCON BIOLOGICS

Biocon Biologics started FY26 on a strong footing, delivering 18% year-on-year revenue growth, driven by robust demand across key markets. EBITDA rose 36% Y-o-Y on a like-to-like basis to Rs 645 crore, with a 300 bps sequential margin improvement, driven by improved operating leverage.

The U.S. FDA approval of Kirsty™ (bAspart) builds on the strong foundation established with Semglee® (bInsulin Glargine), enabling us to offer patients the full range of affordable short and long-acting insulin therapies. With regulatory approvals for our bDenosumab products — Vevzuo® and Efraxy® — in Europe and the UK, Biocon Biologics now has 12 approved biosimilar molecules globally. The launch of Yesafili® (bAflibercept) in Canada marked our entry into ophthalmology and the successful commercialization of our 10th biosimilar globally.
As we enter the 'Accelerate' phase, we are confident in our ability to scale, deepen market presence, and deliver sustained growth." **- Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited.**

SYNGENE

"We delivered a strong first-quarter performance in line with expectations, with revenue from operations growing 11% year-on-year to Rs 875 crore and EBITDA at Rs 224 crore, reporting a growth of 19%. Growth was driven by continued momentum in Research Services, as pilot programs transitioned into long-term contracts. In Biologics manufacturing, operations have commenced at our Unit III facility in Bengaluru, and preparations are advancing for the Bayview facility in the U.S., scheduled to launch later this year. With a positive first quarter start and strategic investments in scientific capabilities, we remain confident in our ability to deliver on our guidance for the year." -***Peter Bains, CEO & Managing Director, Syngene International Limited.***

FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q1FY26

In Rs Crore

Particulars	Q1FY26	Q1FY25	YoY (%)
INCOME			
Generics	697	659	6
Biosimilars	2,458	2,083	18
CRDMO/ Research Services	875	790	11
Inter-segment	(87)	(99)	(13)
Revenue from operations#	3,942	3433	15
Other income@	80	1,134	(93)
Total Revenue	4,022	4,567	15[1]
Net R&D Expenses	205	228	(10)
EBITDA	829	1,755	19[1]
EBITDA Margins	21%	38%	
Core EBITDA$	1,003	903	11
Core EBITDA Margins	25%	26%	
PBT *(before Exceptional Items^)*	97	1,114	72[1]
PBT	97	1,146	
Net Profit *(before Exceptional Items)*	31	648	342[1]
Net Profit *(Reported)*	31	660	65[1]

Figures above are rounded off to the nearest Crore; % based on absolute numbers.

Notes to financials above:

#Revenue from operations includes licensing income

@Other Income in Q1 FY25 includes BFI divestment gain of Rs1,057 Cr

$Core EBITDA is EBITDA net of R&D expense, licensing, forex, BFI divestment gain, and mark-to-market movement on investments

^Exceptional items during Q1 FY25 amount to Rs 32 crore

[1]On a like-for-like basis when excluding BFI divestment gain in Q1 FY25

Financial Commentary: Q1FY26

Operating Revenue for Q1FY26 grew **15%** year-on-year (YoY) to **Rs 3,942 crore**.
Core EBITDA at **Rs 1,003 crore**, grew **11%** with **core operating margins** of **25%.**
Net R&D investments for the quarter were **Rs 205 crore**, representing 7% of revenue ex-Syngene.
EBITDA for the quarter at **Rs 829 crore**, grew* by **19 %** with an **EBITDA margin of 21%** on a like for like basis.
Profit Before Tax before exceptional items stood at **Rs 97 crore,** an increase* of **72%** on a like for like basis
Net Profit for the quarter, before exceptional items, stood at **Rs 31 crore** with a growth* of **342%** on a like for like basis.
Reported Net Profit for the quarter stood at **Rs 31 crore, up* 65%** on a like for like basis.
**Excluding BFI divestment gain*

Corporate Highlights

Biocon successfully concluded its first equity fundraise since the 2004 IPO, raising Rs 4,500 crores through a well-received Qualified Institutions Placement (QIP) in June 2025. The issue saw strong participation from a diverse set of domestic and global investors reflecting their confidence in our growth trajectory and strategic vision. These funds will be used to increase Biocon's holding in Biocon Biologics and provide an exit to the private equity investors in Biocon Biologics.

Management Update

Biocon Biologics

Deepali Naair has joined Biocon Biologics as the Global Head of Brand and Corporate Communications and is a member of the Executive Leadership Team. She brings 30+ years of leadership experience in marketing and corporate reputation management across diverse sectors in India, ASEAN, and Australia. Her appointment strengthens Biocon Biologics' brand and communications function as the company scales its global presence and deepens stakeholder engagement across geographies.

Sustainability

Biocon Limited

Biocon was awarded a gold rating in EcoVadis Corporate Sustainability Assessment, with a score of 77, placing the Company in the top five percentile of organizations assessed worldwide. This is the highest score achieved by the Company and marks a significant milestone in our sustainability journey.

Syngene

Syngene was recognised by TIME magazine and Statista as one of the World's Most Sustainable Companies in 2025. Syngene ranked #1 in India among companies in the pharma and biotech sectors and was ranked in the top 20 life sciences companies globally.

Business Highlights

GENERICS: APIs & Generic Formulations

- **Q1 FY26 Revenue from Operations at Rs 697 Crore, up 6% YoY**
- **Q1FY26 R&D Investment was Rs 70 crore, accounting for 10% of Revenue**

Business Performance

In the U.S., the Company launched its injectable drug product, Micafungin, an echinocandin anti-fungal medication that treats and prevents a range of fungal or yeast infections, and Everolimus (Zortress®) tablets used to prevent kidney and liver transplant rejection.

In India, approval for Liraglutide (gVictoza) was obtained under the Government of India's recently introduced 'Reliance on Recognized Regulatory Authorities' framework, that recognizes approvals granted by established and well-referenced stringent regulatory authorities. This marks the Company's first approval in India for its vertically integrated GLP-1 drug product. The Company is preparing to launch the product through its commercialization partners.

The Company obtained final approval for Rivaroxaban tablets in the U.S., used to treat deep vein thrombosis in adults.

The Company's injectable manufacturing facility primarily focused on GLP-1s in Bangalore has been commissioned with commercialization expected in FY27. The facility will fulfil the business' portfolio needs across vials, cartridges, pre-filled syringes and drug-device combination products, strengthening its capacity to serve its portfolio demands globally.

Regulatory Inspections

ANVISA, Brazil, recently completed regulatory audits at the Company's three API sites in Visakhapatnam (sites 5 and 6) and Bengaluru (site 1) with zero observations.

The Company's oral solid dosage facility in Bengaluru underwent an EU-GMP inspection by the Malta Medicines Authority with one major observation, for which a response has been submitted.

BIOSIMILARS: Biocon Biologics

- **Q1FY26 Revenue from Operations at Rs 2,458 Crore, Up 18% YoY**
- **Q1FY26 EBITDA was Rs 645 Crore; Representing EBITDA Margin of 26%**
- **Q1FY26 R&D Investments was Rs 134 Crore, Accounting for 5% of Revenue**
- **Served 6.0+ Million Patients** *(MAT June 2025 basis)*[##]

[##]12-month moving annual patient population (June 2024 to July 2025)

Business Performance

Biosimilars revenue from operations for Q1FY26 stood at Rs 2,458 crore, an 18% YoY increase, driven by robust demand for our products across geographies. This growth in revenue translated into an EBITDA at Rs 645 crore representing growth of 36% over last year, on like-to-like basis.

EBITDA margin for Q1FY26 stood at 26%, on a like-for-like basis. EBITDA margins excluding forex and other items stood at 24%, with ~300 bps YoY expansion, representing improvement in operating leverage, as we begin to realize the benefits of economies of scale.

The company continues to expand access to its products with 19 approvals and 19 launches globally.

Advanced Markets

Launches and Commercial Performance

North America

Yesafili™ was launched in Canada, as the first biosimilar Aflibercept in the market. This marks Biocon Biologics' 10th biosimilar to be commercialized globally. In the U.S., **Yesintek™** has emerged as an early leader in the immunology space with significant new prescription shares and a strong formulary coverage with large commercial payors. Our oncology portfolio driven by **Ogivri®** (bTrastuzumab) and **Fulphila®** (bPegfilgrastim) continued to see a strong demand.

Europe

In Europe, the company is expanding its footprint and launching new products across the region. **Yesintek™** was launched in key European countries. **Ogivri®** and **Abevmy®** achieved market shares of 21% and 15%, respectively.

JANZ

In **Japan**, **Ustekinumab** BS Subcutaneous Injection [YD] was launched by its strategic partner Yoshindo Inc. **Nepexto®**, a biosimilar to Enbrel® (Etanercept), was launched in Australia through its local partner Generic Health.

Regulatory Approvals

North America:

In the U.S., Biocon Biologics achieved an important milestone with FDA approval for **Kirsty™**, a biosimilar to NovoLog® (Insulin Aspart). It is the first and only interchangeable rapid acting biosimilar Insulin to be approved. Kirsty builds on the strong foundation laid by **Semglee®**, the long-acting insulin analogue and augments the Company's leadership in the Insulins segment in the U.S.

Europe:

Yesafili™ (bAflibercept) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its pre-filled syringe (PFS) presentation. **Yesintek™** (bUstekinumab) received marketing authorization from the UK's

Medicines and Healthcare products Regulatory Agency (MHRA). **Vevzuo®** and **Evfraxy®**, the Company's biosimilars to Denosumab, were granted marketing authorization by both the European Commission (EC**)** and MHRA in the UK which marks Biocon Biologics entry into bone health space.

Emerging Markets

Emerging Markets business remained strong with increased focus on eight high-impact, self-led markets, resulting in a notable increase in revenue contribution in Q1 FY'26 from these markets. The Company executed 12 launches from its commercialized portfolio across the region. It also secured several strategic regulatory approvals and continued to file new product applications across regions, which will pave the way for future growth. The company won important tenders in several countries across APAC, AFMET, and LATAM.

Note:. The data presented here inter alia volumes, projections, market share, is based solely on Biocon Biologics' study, interpretation and conclusion derived through analysis of different data sets from varied sources inter alia IQVIA Q1 CY2025.
–All trademarks, registered or unregistered, are the property of their respective owners.

Contract Research Development & Manufacturing Organization[&] (CRDMO): Syngene

- **Q1FY26 Revenue from Operations at Rs 875 Crore, Up 11% YoY**
- **Q1FY26 EBITDA was Rs 224 Crore; Up 19% YoY**

Business Performance

Our CRDMO business reported a positive start to FY26 with revenue from operations growing 11% year-on-year to Rs 875 crore and EBITDA rising 19%. Growth was primarily driven by the continued conversion of pilot programs into long-term contracts within the Research Services business. The Company also expanded its scientific platform by commissioning a new, state-of-the-art peptide laboratory—strengthening its capabilities across emerging therapeutic modalities such as monoclonal antibodies, ADCs, oligonucleotides, and PROTACs.

The company successfully completed a USFDA Good Clinical Practices (GCP) inspection of its Human Pharmacology Unit with no observations. The Company's Biologics facility at Biocon Park received an Establishment Inspection Report (EIR) with a favourable Voluntary Action Indicated (VAI) outcome.

Note:
[&] Biocon has renamed its Research Services business segment as CRDMO to represent Syngene's business model of a CRO +CMO.

Enclosed: Fact Sheet – with Financials as per IND-AS

About Biocon Limited
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and

commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the U.S., Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com Follow-us on **X** (*formerly Twitter*) @bioconlimited and **LinkedIn**: @BioconLimited for company updates. For FY25 Integrated Annual Report of Biocon click here

Biocon Biologics Limited, a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its 'lab to market' capabilities to serve over 6 million patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.

Biocon Biologics has commercialized 10 biosimilars from its portfolio which are addressing the patients' needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). **Website:** www.bioconbiologics.com; **Follow us on X** *(formerly Twitter)*: @BioconBiologics and **LinkedIn**: Biocon Biologics for company updates.

Syngene International Ltd.
(BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 5600 scientists offer both skills and the capacity to deliver great science, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2.2 Mn sq. ft of specialist discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com For the Company's FY24 Environmental, Social, and Governance (ESG) report, visit https://esgreport.syngeneintl.com/

FOR MORE INFORMATION	
MEDIA	**INVESTORS**
Biocon Group Seema Ahuja SVP, Corporate Communications Chairperson's Office +91 99723 17792 seema.ahuja@biocon.com	**Biocon** Saurabh Paliwal Head - Investor Relations +91 95383 80801 saurabh.paliwal@biocon.com
Biocon **For Generics business** Calvin Printer Head - Corporate Communications +91 70329 69537 calvin.printer@biocon.com	

Earnings Call
The management of the Company will host an Earnings Call on **8th Aug, 2025 at 9:00 AM IST**, over a Zoom Webinar, where the senior management will discuss the Company's performance and answer questions from participants.

Details of the Zoom webinar is given below as well as on the Company website *www.biocon.com* under Investors >> Financial Calendar >> Earnings Call for the period ended June 30, 2025. Transcript of the conference call will be uploaded on the Company website in due course.

Zoom Webinar Details	
Date	**8 Aug 2025**
Time	**9:00 AM IST**
Join Zoom Webinar	Click here to attend earnings call

Forward-Looking Statements: Biocon

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.

BIOCON GROUP

F A C T S H E E T

June - 2025

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT

(Rs. Crores)

Particulars	Q1 FY 26	Q1 FY 25	Variance %
INCOME			
Generics	697	659	6%
Biosimilars	2,458	2,083	18%
CRDMO*	875	790	11%
Inter-segment	(87)	(100)	-13%
Revenue from operations #	**3,942**	**3,433**	**15%**
Other income	80	1,134	-93%
TOTAL REVENUE	**4,022**	**4,567**	**-12%**
EXPENDITURE			
Material & Power costs	1,514	1,276	19%
Staff costs	783	702	12%
Research & Development expenses**	205	228	-10%
Other expenses	692	606	14%
Manufacturing, staff & other expenses	**3,193**	**2,812**	**14%**
EBITDA	**829**	**1,755**	**-53%**
Interest & Finance charges	277	236	17%
Depreciation & Amortisation	455	405	12%
PBT	**97**	**1,114**	**-91%**
Exceptional item	-	32	-100%
PBT	**97**	**1,146**	**-92%**
Taxes	8	273	-97%
Taxes on exceptional item	-	11	0%
NET PROFIT BEFORE MINORITY INTEREST	**89**	**862**	**-90%**
Minority interest	58	193	-70%
Minority interest on exceptional item	-	10	0%
NET PROFIT FOR THE PERIOD	**31**	**660**	**-95%**
EPS Rs.	**0.3**	**5.5**	
NET PROFIT BEFORE EXCEPTIONAL ITEM	**31**	**648**	**-95%**
Exceptional item, net of taxes	-	12	0%
NET PROFIT FOR THE PERIOD	**31**	**660**	**-95%**
# Licensing Income	*4*	*6*	
** Earlier Research Services*			
*** Gross Research & Development expenses*	*205*	*228*	

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT

(Rs. Crores)

Particulars	Q1 FY 26	Q4 FY 25	Variance %
INCOME			
Generics	697	1,048	-34%
Biosimilars	2,458	2,463	0%
CRDMO*	875	1,018	-14%
Inter-segment	(87)	(112)	-22%
Revenue from operations #	**3,942**	**4,417**	**-11%**
Other income	80	37	116%
TOTAL REVENUE	**4,022**	**4,454**	**-10%**
EXPENDITURE			
Material & Power costs	1,514	1,567	-3%
Staff costs	783	765	2%
Research & Development expenses**	205	231	-11%
Other expenses	692	776	-11%
Manufacturing, staff & other expenses	**3,193**	**3,339**	**-4%**
EBITDA	**829**	**1,115**	**-26%**
Interest & Finance charges	277	212	30%
Depreciation & Amortisation	455	436	4%
PBT BEFORE EXCEPTIONAL ITEM	**97**	**466**	**-79%**
Exceptional item, Net	-	21	-100%
PBT	**97**	**487**	**-80%**
Taxes	8	24	-68%
Taxes on exceptional item	-	4	-100%
NET PROFIT BEFORE MINORITY INTEREST	**89**	**459**	**-81%**
Minority interest	58	109	-47%
Minority interest on exceptional item	-	6	-
NET PROFIT FOR THE PERIOD	**31**	**344**	**-91%**
EPS Rs.	**0.3**	**2.9**	
NET PROFIT BEFORE EXCEPTIONAL ITEM	**31**	**333**	**-91%**
Exceptional item	-	11	
NET PROFIT FOR THE PERIOD	**31**	**344**	**-91%**
# Licensing Income	*4*	*8*	
** Earlier Research Services*			
*** Gross Research & Development expenses*	*205*	*231*	

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Crores)

Particulars	Jun 30, 2025	Mar 31, 2025
ASSETS		
Non-current assets		
(a) Property, plant and equipment	8,879	8,708
(b) Capital work-in-progress	4,156	4,102
(c) Right-of-use assets	594	604
(d) Goodwill	16,839	16,786
(e) Other intangible assets	5,733	5,865
(f) Intangible assets under development	4,421	4,407
(g) Financial assets		
Investments	502	680
Derivative assets	190	187
Other financial assets	88	68
(h) Income tax asset, net	405	371
(i) Deferred tax asset, net	222	258
(j) Other non-current assets	397	476
Non-current assets	**42,426**	**42,512**
Current assets		
(a) Inventories	5,756	4,931
(b) Financial assets		
Investments	3,184	447
Trade receivables	5,845	5,488
Cash and cash equivalents	2,337	3,227
Other bank balances	568	893
Derivative assets	99	96
Other financial assets	348	456
(c) Other current assets	832	747
Current assets	**18,969**	**16,285**
TOTAL - ASSETS	**61,395**	**58,797**
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	669	600
(b) Other equity	25,200	21,044
Equity attributable to owners of the Company	**25,869**	**21,644**
Non-controlling interests	6,129	6,069
Total Equity	**31,998**	**27,713**
Non-current liabilities		
(a) Financial liabilities		
Borrowings	10,076	12,405
Lease liabilities	537	539
Derivative liabilities	63	23
Other financial liabilities	1,379	2,828
(b) Other non-current liabilities	332	336
(c) Provisions	236	261
(d) Deferred tax liability, net	225	358
Non-current liabilities	**12,848**	**16,750**
Current liabilities		
(a) Financial liabilities		
Borrowings	5,753	5,350
Lease liabilities	67	67
Trade payables	6,941	6,549
Derivative liabilities	156	46
Other financial liabilities	2,247	933
(b) Other current liabilities	953	1,024
(c) Provisions	190	192
(d) Income tax liability, net	242	173
Current liabilities	**16,549**	**14,334**
TOTAL - EQUITY AND LIABILITIES	**61,395**	**58,797**